Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-12-26
2006-12-26
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S133100, C424S138100, C424S141100, C424S143100, C424S144100, C424S155100, C424S173100, C424S174100, C530S387100, C530S387300, C530S387700, C530S388100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388800
Reexamination Certificate
active
07153508
ABSTRACT:
The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signaling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.
REFERENCES:
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5116964 (1992-05-01), Capon et al.
patent: 5304635 (1994-04-01), Imam
patent: 5844095 (1998-12-01), Linsley et al.
patent: 5885579 (1999-03-01), Linsley et al.
patent: 6051228 (2000-04-01), Aruffo et al.
patent: 6162432 (2000-12-01), Wallner et al.
patent: 0 173 494 (1986-03-01), None
patent: 0 194 276 (1986-03-01), None
patent: 0 451 216 (1991-10-01), None
patent: 0 171 496 (1993-05-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 555 880 (1993-08-01), None
patent: 0 239 400 (1994-08-01), None
patent: 0 682 040 (1995-11-01), None
patent: 2 177 096 (1986-03-01), None
patent: WO 92/06193 (1992-04-01), None
patent: WO 93/09812 (1993-05-01), None
patent: WO 94/28912 (1994-12-01), None
patent: WO 95/06481 (1995-03-01), None
patent: WO 95/06666 (1995-03-01), None
patent: WO 98/19706 (1998-05-01), None
Mehta et al. Cellular Immunology 155:95-110(1994).
Weiner et al. Expert Opin. Biol. Ther. 4: 375-385 (2004).
Armitage, et al., “Molecular and biologial characterization of a murine,”Nature, 1992, 357 80-82.
Ben-Nun, et al. “The rapid isolation of clonable antigen-specific T lymphocyte lines capable of mediating autoimmune encephalomyelitis,”Eur. J. Immunol., 1981, 11, 195-199.
Blazar, et al., “Infusion of anti-B7.1 (CD80) and anti-B7 2 (CD86) monoclonal antibodies inhibits murine graft-versus-host disease lethality in part via direct effects on CD4+ and CD8+ T cells,”J. Immunol., 1996, 157 3250-3259.
Capon, et al., “Designing CD4 immunoadhesions for AIDS therapy,”Nature, 1989, 337, 525-531.
Cohen, J., New protein steals the show as ‘costimulator’ of T cells, Science, (1993) 262 844-845.
Dautigny, et al., “Molecular cloning and nucleotide sequence of a cDNA clone coding for rat brain myelin proteolipid,”FEBS Lett., 1985. 188(1):33-36.
Delabie, et al. “The B7/BB1 antigen is expressed by Reed-Sternberg cells of Hodgkin's disease and contributes to the stimulating capacity of Hodgkin's disease-derived cell lines.”Blood, 1993, 82:2845-52.
Dillman, et al, “Antibodies as cytotoxic therapy,”J Clin. Oncol., 1994. 12 1497-1515.
Durie, et al., “The role of CD40 and its ligand (gp39) in peripheral and central tolerance and its contribution to autoimmune disease,”Research in Immunology, 1994, 145(3), 200-205 & 244-249.
Durie, et al. “Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40,”Science, 1993, 261:1328-1330.
Falini, et al., “Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin,”Lancet, 1992, 339. 1195-1196.
Freeman, et al., “Uncovering of functional alternative CTLA-4 counter-receptor in B7-deficient mice,”Science, 1993, 262:907-909.
Freeman, et al., “Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation,”Science, 1993, 262 909-911.
Gerritse, et al., “CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis,”Proc Natl. Acad Sci. USA, 1996, 93.2499-2504.
Gottlieb, et al., “Results of a single-dose dose-escalating trial of an anti-B7.1 antibody (IDEC-114) in patients with psoriasis,”J. Invest. Dermatol., 2000, 114.840, Abstract No. 548.
Gottlieb, et al., “Clinical and histologic response to single-dose treatment of moderate to severe psoriasis with an anti-CD80 monoclonal antibody,”J. Am. Acad. Dermatol., 2002. 47:693-700.
Guinan, et al., “Pivotal role of the B7:CD28 pathway in transplantation tolerance and tumor immunity,”Blood, 1994, 84:3261-3282.
Hafler, et al., “The potential of restricted T cell recognition of myelin basis protein epitopes in the therapy of multiple sclerosis,”Ann. NY Acad. Sci, 1991, 636:251-265.
Hariharan, et al. “Therapeutic activity of IDEC-114 (anti-CD80) and rituximab (Rituxan®) in B-cell lymphoma,”Blood, 2001, 98 (11 part 1), p. 608a (abstract).
Hathcock, et al., “Identification of an alternative CTLA-4 ligand costimulatory for T cell activation,”Science, 1993, 282:905-907.
Hollenbaugh, et al., “The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor expression of a soluble form of gp39 with B cell co-stimulatory activity,”EMBO J., 1992, 11(12) 4313-4321.
Kahan. “Immunosuppressive therapy,”Curr Opin Immunol., 1992, 4:553-560.
Karpus, et al. “CD4+ suppressor cells differentially affect the production of IFN-γ by effector cells of experimental autoimmune encephalomyelitis,”J. Immunol., 1989, 143:3492-3497.
Kuntz, “Structure-based strategies for drug design and discovery,”Science, 1992, 257:1078-82.
Laman, et al., “The role of gp39 (CD40 ligand) in EAE and MS,”Journal of Neuroimmunology, 1994, 54(1-2):175.
Lederman, et al. “Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (Help),”J Exp. Med.1992, 175:1091-1101.
Lider, et al., “Suppression of experimental autoimmune encephalomyelitis by oral administration of myelin basic protein,”J. Immunol., 1989, 142:748-752.
Linsley, et al., “The role of the CD28 receptor during T cell responses to antigen,”Ann. Rev Immunol., 1993, 11:191-212.
Liu, et al., “Blockade of CD28/CTLA-4-B7 co-stimulatory pathway in colitic SCID mice,”Digestive Disease Week, May 21-24, 2000, p. A58, Abstract No. 2000.
McCafferty, et al., “Phage antibodies. filamentous phage displaying antibody variable domains,”Nature, 1990, 348 552-554.
Miller, et al., “Antigen-driven bystander suppression after oral administration of antigens,”J Exp. Med., 1991, 174:791-798.
Mokhtarion, et al., “Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice,”Nature, 1984, 309:356-358.
Morrison, et al., “Chimeric human antibody molecules mouse antigen-binding domains with human constant region domains,”Proc. Natl. Acad. Sci USA, 1985, 81:6851-6855.
Munro, et al, “In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease,”Blood, 1994, 83:793-798.
Ngo, et al., In Merz, Jr. and Le Grand (eds),The Protein Folding Problem and Tertiary Structure Prediction, Birkhauser, Boston, MA, pp. 433 & 492-495.
Nickoloff, et al., “T lymphocytes in skin lesions of psoriasis and mycosis fungoides express B7-1: a ligand for CD28,”Blood, 1994, 83:2580-2586.
Noelle, et al., “A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells,”Proc. Natl. Acad. Sci. USA, 1992, 89:6550-6554.
Olsson, et al., “Human-human monoclonal antibody-producing hybridomas, technical aspects,”Meth. Enzymol., 1982 92 3-17.
Pemn, et al., “Opposing effects of CTLA4-lg and anti-CD80 (
Anderson Darrell R.
Brams Peter
Hanna Nabil
Biogen Idec Inc.
Gambel Phillip
Pillsbury Winthrop Shaw & Pittman LLP
LandOfFree
Treatment of B cell lymphoma using anti-CD80 antibodies that... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of B cell lymphoma using anti-CD80 antibodies that..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of B cell lymphoma using anti-CD80 antibodies that... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3670073